Literature DB >> 27570237

Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine.

Olubukola T Idoko1, Lee M Hampton2, Robert B Mboizi3, Schadrac C Agbla3, Aaron S Wallace2, Jennifer B Harris2, Dawda Sowe4, Daniel C Ehlman2, Beate Kampmann5, Martin O Ota6, Terri B Hyde2.   

Abstract

BACKGROUND: As the World Health Organization (WHO) currently recommends that children be protected against 11 different pathogens, it is becoming increasingly necessary to administer multiple injectable vaccines during a single immunization visit. In this study we assess Gambian healthcare providers' and infant caregivers' attitudes and practices related to the administration of multiple injectable vaccines to a child at a single immunization visit before and after the 2015 introduction of inactivated polio vaccine (IPV). IPV introduction increased the number of injectable vaccines recommended for the 4-month immunization visit from two to three in The Gambia.
METHODS: We conducted a cross-sectional questionnaire-based survey before and after the introduction of IPV at 4months of age in a representative sample of all health facilities providing immunizations in The Gambia. Healthcare providers who administer vaccines at the selected health facilities and caregivers who brought infants for their 4month immunization visit were surveyed.
FINDINGS: Prior to IPV introduction, 9.9% of healthcare providers and 35.7% of infant caregivers expressed concern about a child receiving more than 2 injections in a single visit. Nevertheless, 98.8% and 90.9% of infants received all required vaccinations for the visit before and after IPV introduction, respectively. The only reason why vaccines were not received was vaccine stock-outs. Infant caregivers generally agreed that vaccinators could be trusted to provide accurate information regarding the number of vaccines that a child needed.
CONCLUSION: Healthcare providers and infant caregivers in this resource limited setting accepted an increase in the number of injectable vaccines administered at a single visit even though some expressed concerns about the increase. Published by Elsevier Ltd.

Entities:  

Keywords:  Acceptance; Caregivers; Healthcare providers; Multiple injectable vaccines; Single visit; The Gambia

Mesh:

Substances:

Year:  2016        PMID: 27570237     DOI: 10.1016/j.vaccine.2016.07.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-naïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial].

Authors:  Ikechukwu Adigweme; Edem Akpalu; Mohammed Yisa; Simon Donkor; Lamin B Jarju; Baba Danso; Anthony Mendy; David Jeffries; Abdoulie Njie; Andrew Bruce; Michael Royals; James L Goodson; Mark R Prausnitz; Devin McAllister; Paul A Rota; Sebastien Henry; Ed Clarke
Journal:  Trials       Date:  2022-09-14       Impact factor: 2.728

2.  Acceptance of the Administration of Multiple Injectable Vaccines in a Single Immunization Visit in Albania.

Authors:  Iria Preza; Saleena Subaiya; Jennifer B Harris; Daniel C Ehlman; Kathleen Wannemuehler; Aaron S Wallace; Shahin Huseynov; Terri B Hyde; Erida Nelaj; Silvia Bino; Lee M Hampton
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

3.  Lessons Learned From Managing the Planning and Implementation of Inactivated Polio Vaccine Introduction in Support of the Polio Endgame.

Authors:  Simona Zipursky; Manish Patel; Margaret Farrell; Alejandro Ramirez Gonzalez; Tasleem Kachra; Yann Folly; Feyrouz Kurji; Chantal Laroche Veira; Emily Wootton; Lee M Hampton
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

4.  Polio Endgame: Lessons Learned From the Immunization Systems Management Group.

Authors:  Simona Zipursky; Jos Vandelaer; Alan Brooks; Vance Dietz; Tasleem Kachra; Margaret Farrell; Ann Ottosen; John L Sever; Michel J Zaffran
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

5.  Assessing Inactivated Polio Vaccine Introduction and Utilization in Kano State, Nigeria, April-November 2015.

Authors:  Lynda U Osadebe; Adam MacNeil; Hashim Elmousaad; Lora Davis; Jibrin M Idris; Suleiman A Haladu; Olorunsogo B Adeoye; Patrick Nguku; Uneratu Aliu-Mamudu; Elizabeth Hassan; John Vertefeuille; Peter Bloland
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

Review 6.  Administering Multiple Injectable Vaccines During a Single Visit-Summary of Findings From the Accelerated Introduction of Inactivated Polio Vaccine Globally.

Authors:  Samantha B Dolan; Manish Patel; Lee M Hampton; Eleanor Burnett; Daniel C Ehlman; Julie Garon; Emily Cloessner; Elizabeth Chmielewski; Terri B Hyde; Carsten Mantel; Aaron S Wallace
Journal:  J Infect Dis       Date:  2017-07-01       Impact factor: 5.226

7.  Introduction of inactivated poliovirus vaccine in the Philippines: Effect on health care provider and infant caregiver attitudes and practices.

Authors:  Anna Lena Lopez; Jennifer B Harris; Peter Francis Raguindin; Josephine Aldaba; Merrylle Morales; Patrick Sylim; Kathleen Wannemuehler; Aaron Wallace; Daniel C Ehlman; Terri B Hyde; Kimberley K Fox; Batmunkh Nyambat; Maria Joyce Ducusin; Lee M Hampton
Journal:  Vaccine       Date:  2018-10-24       Impact factor: 3.641

8.  Factors associated with the utilization of inactivated polio vaccine among children aged 12 to 23 months in Kalungu District, Uganda.

Authors:  Mirembe Rachel Faith; Babirye Juliet; Nathan Tumuhamye; Tumwebaze Mathias; Emma Sacks
Journal:  Health Policy Plan       Date:  2020-11-01       Impact factor: 3.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.